1. Academic Validation
  2. Design and synthesis of 2-phenylpyrimidine coumarin derivatives as anticancer agents

Design and synthesis of 2-phenylpyrimidine coumarin derivatives as anticancer agents

  • Bioorg Med Chem Lett. 2017 Oct 1;27(19):4578-4581. doi: 10.1016/j.bmcl.2017.08.044.
Na Lv 1 Ming Sun 2 Chen Liu 3 Jiabin Li 4
Affiliations

Affiliations

  • 1 Department of Stomatology, First Affiliated Hospital of Anhui Medical University, Hefei 230032, China; Department of Infectious, First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
  • 2 Department of Stomatology, First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
  • 3 College of Basic Medicine, Anhui Medical University, Hefei 230032, China.
  • 4 Department of Infectious, First Affiliated Hospital of Anhui Medical University, Hefei 230032, China. Electronic address: [email protected].
Abstract

A series of 2-phenylpyrimidine coumarin derivatives with potential telomerase-inhibiting activity was designed and synthesized. All of the compounds were screened for antiproliferative activity against CNE2, KB, and Cal27 cell lines in vitro. The results showed that most of the derivatives had a favorable effect on resisting tumor cell proliferation; compound 13, 3-(4-amino-5-oxo-5H-chromeno[4,3-d]pyrimidin-2-yl)phenyl 4-(dimethylamino)benzenesulfonate, exhibited the best activity. Flow cytometry revealed that compound 13 can inhibit CNE2 proliferation. Telomerase inhibition and in vitro antitumor activity were consistent among the compounds, but compound 13 showed the best telomerase-inhibiting activity and could inhibit telomere extension. Molecular docking results indicated that compound 13 bonded with telomerase Reverse Transcriptase (TERT) through multiple interactions, including hydrogen bonding and hydrophobic interactions. The results of the study provide further information on 2-phenylpyrimidine Coumarins, expanding the types of Telomerase inhibitors as the parent structures.

Keywords

2-Phenylpyrimidine coumarin derivatives; Antiproliferative; Telomerase inhibitors.

Figures